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To the Editor: Community-ac-
quired methicillin-resistant Staphy-
lococcus aureus (CA-MRSA), which 
carries genes for Panton-Valentine 
leukocidin (PVL), has become a major 
concern worldwide (1–3). CA-MRSA 
is mainly associated with skin and soft 
tissue infections in young, otherwise 
healthy, persons in the community (3) 
and also with life-threatening sepsis 
and community-acquired pneumo-
nia (preceded by inﬂ  uenza)  (1,3,4). 
The role of PVL in the pathogenesis 
of staphylococcal infections is con-
troversial. Whereas Labandeira-Rey 
et al. (5) provided data that PVL, in 
combination with staphylococcal 
protein A, destroys respiratory tissue 
and bacteria-engulﬁ  ng immune cells, 
Voyich et al. (6) and Bubeck Warden-
burg et al. (7) showed that PVL was 
not essential for the pathogenesis of 
skin disease, sepsis, or pneumonia in 
a mouse model.
Several types of CA-MRSA 
clones exist, e.g., CA-MRSA belong-
ing to multilocus sequence type (ST) 
1 (called the USA400 clone) and ST8 
(called the USA300 clone), which have 
been major clones in North America 
(recently, USA300 is becoming more 
prominent); CA-MRSA belonging to 
ST80, which has been a major clone in 
Europe; and CA-MRSA belonging to 
ST30, which is distributed worldwide, 
including Japan (2,8). MRSA carrying 
the PVL gene (a marker of CA-MRSA 
[ST30]) comprises 0.1% of MRSA 
isolated in hospitals in Japan (9).We 
describe a fatal case of pediatric pneu-
monia and septic shock from CA-MR-
SA in Japan.
A 16-month-old, previously 
healthy boy was admitted to the hos-
pital for fever and shortness of breath 
on August 30, 2006. He had had cold-
like symptoms for 14 days and fever 
for the 2 previous days. On examina-
tion, hordeolum of the right eyelid and 
cyanosis were observed; the patient’s 
blood pressure was 106/ (undetect-
able) mm Hg, tachycardia 185 beats/
min, tachypnea 72 breaths/min, and 
temperature 39.8°C. He had bilateral 
coarse breath sounds, and broncho-
vesicular breath sounds over the right 
lung. Chest radiography indicated lo-
bar consolidation and pleural effusion 
on the right side. Laboratory analysis 
showed leukocytopenia, thrombocy-
topenia, elevated C-reactive protein 
level, and hypoxemia. 
Intravenous administration of 
sulbactam/ampicillin and cefotaxime, 
and oxygen inhalation was started. 
Oxygen saturation did not improve, 
and laboratory values of disseminated 
intravascular coagulation (DIC) were 
observed: platelet count 121 K/mm3, 
ﬁ   brinogen level 528 mg/dL, ﬁ  brin 
degradation products 37.7 μg/mL, 
prothrombin time 1.86 international 
normalized ratio, and D-dimer 37.7 
μg/mL. The condition was considered 
septic shock, and consequently the boy 
was transferred to the pediatric inten-
sive care unit, where he required intu-
bation and mechanical ventilation.
Sulbactam/ampicillin was switched 
to meropenem, and cefotaxime was 
continued. On day 2 after admission, 
chest radiography showed bilateral 
consolidation. On day 3, blood culture 
yielded MRSA, and cefotaxime was 
changed to vancomycin. Meropenem 
therapy was continued to cover pos-
sible mixed bacterial infection. Immu-
noglobulin therapy and DIC syndrome 
treatment (nafamostat mesilate, ulinas-
tatin, freeze-dried concentrated human 
antithrombin III) were also started. 
On day 4, computed tomographic ex-
amination detected pneumothorax and 
athelectasis. Because laboratory data 
conﬁ  rmed the presence of only MRSA, 
meropenem was changed to ﬂ  omoxef 
(which belongs to the oxacephem fam-
ily of β-lactam antimicrobial agents) 
on the expectation that a possible syn-
ergistic effect of ﬂ  omoxef and vanco-
mycin might occur. No major changes 
occurred on days 5 and 6. On day 7, in 
addition to bilateral inﬁ  ltrates on chest 
radiography, the oxygen index was 65 
(partial pressure of arterial oxygen/
fraction of inspired oxygen), and the 
patient was considered to have acute 
respiratory distress syndrome. A per-
cutaneous cardiopulmonary support 
system (a portable heart-lung machine 
that provides temporary circulatory 
support) was used, but in spite of treat-
ment, there was no improvement, and 
the child died on day 10 after admis-
sion (September 8). An autopsy was 
not performed. 
Molecular characterization of 
MRSA isolated from the blood was 
performed as described previously 
(8,9). Isolated MRSA (strain NN32) 
was positive for PVL, belonging to 
ST30:spa19:staphylococcal cassette 
chromosome mec (SCCmec)IVa, and 
was resistant to only β-lactam antimi-
crobial agents (Table).
To date, all cases of PVL-positive 
CA-MRSA infections ofﬁ  cially report-
ed in Japan were caused by strains be-
longing to ST30 (9). All these strains 
can be classiﬁ  ed into 2 types on the 
basis of spa type (Table), for example, 
ST30:spa19:SCCmecIVc. This type 
includes strain NN1, isolated from an 
11-month-old patient with bullous im-
petigo (8); strain NN12, isolated from a 
17-year-old patient with cutaneous ab-
scess/osteomyelitis (8); strain NN31, 
isolated from an 18-year-old patient 
with pelvic abscesses (9); and strain 
EB00449, isolated from a 27-year-old 
patient with cutaneous abscesses (9). 
Another type is ST765 (single locus 
variant of ST30):spa43:SCCmecIVx. 
This type includes strain DB00319, 
isolated from a 61-year-old hospital 
inpatient (9).
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The molecular characteristics of 
strain NN32 were similar to those of 
strain NN1, except for SCCmecIV sub-
types (Table). Moreover, pulsed-ﬁ  eld 
gel electrophoresis patterns (data not 
shown) and the PVL gene sequences 
of the 2 strains (NN32 and NN1) were 
identical (Table).
This case of CA-MRSA ST30 in-
fection in a child represents a progres-
sion from common cold–like symp-
toms (occurring outside the inﬂ  uenza 
season) to fatal pneumonia, despite 
intensive therapy, including the ad-
ministration of sensitive antimicrobial 
agents. CA-MRSA ST30 contains sev-
eral genes that mediate adhesion (e.g., 
cna and bbp) and toxin genes (PVL 
and egc, which encode for at least 5 
superantigens, including staphylococ-
cal enterotoxin G, I, M, N, and O). 
The gene cluster egc is associated 
with septic shock (10). Further studies 
are needed to clarify the pathogenesis 
of community-acquired pneumonia 
caused by CA-MRSA.
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Table. Characteristics of PVL-positive MRSA strains reported in Japan since 2000* 
PVL-positive MRSA 
Present strain  Previous strains 
Type, gene, or resistance  NN32 NN1 NN12, NN31 EB 00449 DB 00319
Types CC 30 30 30 30 30
ST 30 30 30 30 765
spa 19 19 19 19 43
agr 33 3 3 3
SCCmec IVa IVc IVc IVc IVx*
Coagulase IV IV IV IV IV
Toxins
 Leukocidins lukS-PV, lukF-PV†+ + + ++
lukE-lukD, lukM –– – – –
 Hemolysins hla, hlg, hld ++ + + +
hlb –– – – +
hlg–v –– – – –
 Staphylococcal  enterotoxins sea –– – – +
tst, seb, sec,
sed, see, seh,
sej, sek, sep
–– – – –
egc‡+ + + + +
seu ++ + + +
 Exfoliative  toxins eta, etb, etd –– – – –
 Others set ++ + + +
edin –– – – –
Adhesins
icaA, sdrD, sdrE –– – – –
icaD, cna,§
eno, fnbA, 
fnbB, ebpS, 
clfA, clfB, fib,  
sdrC, bbp¶
++ + + +
Aminoglycosides GEN#
KAN#*
GEN** 
KAN**
STR**
Macrolides ERY**
Lincosamides CLI**
Tetracycline TET#
Drug resistance and 
penicillinase plasmid 
Penicillinase plasmid 
(kb)
+
(33)
+
(33)
+
(33)
+
(33)
+
(40)**
*PVL, Panton-Valentine leukocidin; MRSA, methicillin-resistant Staphylococcus aureus; SCCmec IVx, staphylococcal cassette chromosome mec type IV 
with unknown subtypes; +, positive; –, negative; GEN, gentamicin; KAN, kanamycin; STR, streptomycin; ERY, erythromycin; CLI, clindamycin; TET, 
tetracycline. 
†GenBank accession nos. for the PVL gene sequences from strains NN32 and NN1 are AB286959 and AB186917, respectively. 
‡egc, enterotoxin gene cluster, including seg, sei, sem, sen, and seo genes. 
§cna, gene encoding for collagen binding protein (adhesin). 
¶bbp, gene encoding for bone sialoprotein binding protein (adhesin). 
#Drug resistance encoded by a conjugative drug resistance plasmid (pGKT1) (8).
**Multidrug-resistant penicillinase plasmid encoding for resistance to GEN, KAN, STR, ERY, and CLI, in addition to penicillin resistance (9). LETTERS
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Rarity of Inﬂ  uenza 
A Virus in Spring 
Shorebirds, 
Southern Alaska
To the Editor: Knowledge of 
avian inﬂ  uenza (AI) virus and its host 
epidemiology and ecology is essential 
for effective monitoring and mitiga-
tion (1). Applicability of global and 
continental-scale models will be key 
for expanding this knowledge base. 
Research in the Delaware Bay area, 
eastern United States, suggests an 
ecologic and epidemiologic viewpoint 
of AI virus in wild birds in which 
shorebirds (family Scolopacidae) are 
predominant hosts in spring; however, 
research in Alberta, Canada, suggests 
that waterfowl are such in autumn 
(2,3). AI virus surveillance in Europe 
(4) suggests that the spring aspect of 
this scenario does not apply there. To 
increase knowledge of AI transport 
among shorebirds in spring in the 
North Paciﬁ  c, we conducted AI virus 
surveillance during the springs of 2006 
and 2007 at the Copper River Delta 
area of Alaska. Millions of birds con-
gregate at this location in the spring, 
resulting in the highest spring shore-
bird concentrations in the New World 
(5). We also sampled gulls (Laridae), 
which are common and heretofore un-
surveyed for AI in this ecosystem.
In 2006 and 2007, 1,050 shorebirds 
(Western Sandpiper, Calidris mauri, 
and Least Sandpiper, C. minutilla) and 
770 Glaucous-winged Gulls (Larus 
glaucescens) were sampled during peak 
spring migration at Hartney Bay, Cor-
dova, Alaska (60°28′N 146°8′W; Ta-
ble). Fresh fecal samples were obtained 
from tidal ﬂ  ats within <1 to 90 min af-
ter identiﬁ  ed ﬂ  ocks were dispersed, and 
samples were placed in sterile medium 
(brain heart infusion buffer with 10,000 
U/mL penicillin G, 1 mg/mL gentami-
cin, and 20 μg/mL amphotericin B) and 
either kept cool (<1 week) before trans-
port to Fairbanks (2006) or placed into 
liquid nitrogen within 2 h of collection 
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Letters
Letters commenting on recent 
articles as well as letters report-
ing cases, outbreaks, or original 
research are welcome. Letters 
commenting on articles should 
contain no more than 300 words 
and 5 references; they are more 
likely to be published if submitted 
within 4 weeks of the original ar-
ticle’s publication. Letters report-
ing cases, outbreaks, or original 
research should contain no more 
than 800 words and 10 references. 
They may have one Figure or Ta-
ble and should not be divided into 
sections. All letters should contain 
material not previously published 
and include a word count.